China factory Erlotinib hydrochloride CAS:183319-69-9 Tarceva in stock
Erlotinib HCl ; Tarceva; Erlotinib Hydrochloride Salt ; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine hydrochloride
Erlotinib hydrochloride CAS: 183319-69-9 is the hydrochloride salt of a quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.
Erlotinib hydrochloride CAS: 183319-69-9 is a quinazoline derivative and antineoplastic agent that functions as a protein kinase inhibitor for EGFR associated tyrosine kinase. It is used in the treatment of non-small cell lung cancer.It potently inhibits EGFR activation in intact cells including HNS human head and neck tumor cells (IC50 20nM), DiFi humancolon cancer cells andMDA MB-468 human breast cancer cells.
Erlotinib hydrochloride CAS: 183319-69-9 is derived from erlotinib CAS: 183321-74-6. Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva.